NCT01133574

This is a Single Ascending Dose Tolerance Study

A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Abbott · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)

Detailed description

The Part A of this study is a parallel design followed in a second part by a cross-over design

Conditions

• Cognition Disorders

Interventions

Type	Name	Description
DRUG	SLV354 capsules	20 mg
DRUG	SLV354 capsules	60 mg
DRUG	SLV354 capsules	120 mg
DRUG	SLV354 capsules	250 mg
DRUG	SLV354 capsules	500 mg
DRUG	SLV354 capsules	750 mg
DRUG	SLV354 capsules	1000 mg
DRUG	SLV354 capsules	1250 mg
DRUG	Placebo capsules	placebo
DRUG	SLV354 capsules	low dose group 1
DRUG	SLV354 capsules	high dose group 1
DRUG	SLV354 capsules	low dose group 2
DRUG	SLV354 capsules	high dose group 2
DRUG	Placebo capsules	placebo

Timeline

• Start date: 2010-02-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2010-05-31
• Last updated: 2011-08-29

Locations

1 site across 1 country: United Kingdom